PDS Biotechnology to Present at the HC Wainwright 23rd Annual Global Investment Conference
September 07 2021 - 8:30AM
PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage
immunotherapy company developing novel cancer therapies based on
the Company’s proprietary Versamune® T-cell activating technology,
announced today that its management will present at the HC
Wainwright 23rd Annual Global Investment Conference.
The presentation will provide an update on
the three ongoing PDS0101 Phase 2 clinical trials. The talk will
also provide updates on progression of two other investigational
pipeline products PDS0102 (Versamune®-TARP) and PDS0103
(Versamune®-MUC1) into human clinical trials. The conference is
taking place virtually from September 13 - 15, 2021.
HC Wainwright 23rd Annual Global
Investment Conference:Investors can register for the
conference HERE.
The presentation will be available on demand
beginning at 7:00 am EDT on Monday, September 13, 2021 within the
Investor section of the company’s website,
https://pdsbiotech.com/.
About PDS BiotechnologyPDS
Biotech is a clinical-stage immunotherapy company developing a
growing pipeline of cancer immunotherapies based on the Company’s
proprietary Versamune® T-cell activating technology platform. Our
Versamune®-based products have demonstrated the potential to
overcome the limitations of current immunotherapy by inducing in
vivo, large quantities of high-quality, highly potent
polyfunctional tumor specific CD4+ helper and CD8+ killer T-cells.
PDS Biotech has developed multiple therapies, based on combinations
of Versamune® and disease-specific antigens, designed to train the
immune system to better recognize diseased cells and effectively
attack and destroy them. The company’s pipeline products address
various cancers including breast, colon, lung, prostate and ovarian
cancers. To learn more, please visit www.pdsbiotech.com or
follow us on Twitter at @PDSBiotech.
About PDS0101PDS Biotech’s lead
candidate, PDS0101, combines the utility of the Versamune® platform
with targeted antigens in HPV-expressing cancers. In partnership
with Merck & Co., PDS Biotech is evaluating a combination of
PDS0101 and KEYTRUDA® in a Phase 2 study in first-line treatment of
recurrent or metastatic head and neck cancer. PDS Biotech is also
conducting two additional Phase 2 studies in advanced
HPV-associated cancers and advanced localized cervical cancer with
the National Cancer Institute (NCI) and The University of Texas MD
Anderson Cancer Center, respectively.
Media & Investor Relations
Contact:Deanne RandolphPDS BiotechPhone: +1 (908)
517-3613Email: drandolph@pdsbiotech.com
Rich CockrellCG CapitalPhone: +1 (404)
736-3838 Email: rich@cg.capital
PDS Biotechnology (NASDAQ:PDSB)
Historical Stock Chart
From Aug 2024 to Sep 2024
PDS Biotechnology (NASDAQ:PDSB)
Historical Stock Chart
From Sep 2023 to Sep 2024